197 related articles for article (PubMed ID: 21239475)
1. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
Anderson VE; Walton MI; Eve PD; Boxall KJ; Antoni L; Caldwell JJ; Aherne W; Pearl LH; Oliver AW; Collins I; Garrett MD
Cancer Res; 2011 Jan; 71(2):463-72. PubMed ID: 21239475
[TBL] [Abstract][Full Text] [Related]
2. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].
Jobson AG; Lountos GT; Lorenzi PL; Llamas J; Connelly J; Cerna D; Tropea JE; Onda A; Zoppoli G; Kondapaka S; Zhang G; Caplen NJ; Cardellina JH; Yoo SS; Monks A; Self C; Waugh DS; Shoemaker RH; Pommier Y
J Pharmacol Exp Ther; 2009 Dec; 331(3):816-26. PubMed ID: 19741151
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibition during alkylation-induced genotoxic stress signals a cell cycle checkpoint response mediated by ATM.
Carrozza MJ; Stefanick DF; Horton JK; Kedar PS; Wilson SH
DNA Repair (Amst); 2009 Nov; 8(11):1264-72. PubMed ID: 19717351
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.
Caldwell JJ; Welsh EJ; Matijssen C; Anderson VE; Antoni L; Boxall K; Urban F; Hayes A; Raynaud FI; Rigoreau LJ; Raynham T; Aherne GW; Pearl LH; Oliver AW; Garrett MD; Collins I
J Med Chem; 2011 Jan; 54(2):580-90. PubMed ID: 21186793
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
[TBL] [Abstract][Full Text] [Related]
6. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.
Huang M; Miao ZH; Zhu H; Cai YJ; Lu W; Ding J
Mol Cancer Ther; 2008 Jun; 7(6):1440-9. PubMed ID: 18566216
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.
Lountos GT; Tropea JE; Zhang D; Jobson AG; Pommier Y; Shoemaker RH; Waugh DS
Protein Sci; 2009 Jan; 18(1):92-100. PubMed ID: 19177354
[TBL] [Abstract][Full Text] [Related]
8. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
[TBL] [Abstract][Full Text] [Related]
9. Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.
Höglund A; Strömvall K; Li Y; Forshell LP; Nilsson JA
Cell Cycle; 2011 Oct; 10(20):3598-607. PubMed ID: 22030621
[TBL] [Abstract][Full Text] [Related]
10. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Sabisz M; Wesierska-Gadek J; Skladanowski A
Biochem Pharmacol; 2010 May; 79(10):1387-97. PubMed ID: 20067769
[TBL] [Abstract][Full Text] [Related]
11. The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
Mini E; Landini I; Lucarini L; Lapucci A; Napoli C; Perrone G; Tassi R; Masini E; Moroni F; Nobili S
Oncol Res; 2017 Nov; 25(9):1441-1451. PubMed ID: 28429680
[TBL] [Abstract][Full Text] [Related]
12. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
Boulton S; Kyle S; Durkacz BW
Carcinogenesis; 1999 Feb; 20(2):199-203. PubMed ID: 10069454
[TBL] [Abstract][Full Text] [Related]
13. Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks.
Heacock ML; Stefanick DF; Horton JK; Wilson SH
DNA Repair (Amst); 2010 Aug; 9(8):929-36. PubMed ID: 20573551
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
J Struct Biol; 2011 Dec; 176(3):292-301. PubMed ID: 21963792
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.
Aris SM; Pommier Y
Cancer Res; 2012 Feb; 72(4):979-89. PubMed ID: 22189968
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
Jobson AG; Cardellina JH; Scudiero D; Kondapaka S; Zhang H; Kim H; Shoemaker R; Pommier Y
Mol Pharmacol; 2007 Oct; 72(4):876-84. PubMed ID: 17616632
[TBL] [Abstract][Full Text] [Related]
17. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.
Zhao H; Traganos F; Darzynkiewicz Z
Cell Cycle; 2008 Oct; 7(19):3048-55. PubMed ID: 18802408
[TBL] [Abstract][Full Text] [Related]
19. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
Bowman KJ; White A; Golding BT; Griffin RJ; Curtin NJ
Br J Cancer; 1998 Nov; 78(10):1269-77. PubMed ID: 9823965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
